Li D, Saldeen T, Romeo F, Mehta J L
Departments of Medicine and Physiology, University of Arkansas and VA Medical Center, Little Rock, USA.
Circulation. 2000 Oct 17;102(16):1970-6. doi: 10.1161/01.cir.102.16.1970.
We demonstrated earlier that angiotensin II (Ang II), by AT(1) receptor activation, upregulates oxidized LDL (ox-LDL) endothelial receptor LOX-1 gene expression and uptake of ox-LDL in human coronary artery endothelial cells (HCAECs). In this study, we investigated the regulation of Ang II receptors (AT1R and AT2R) by ox-LDL and the role of the redox-sensitive transcription factor NF-kappaB in this process.
HCAECs were incubated with ox-LDL for 24 hours. Ox-LDL (10 to 40 microg protein/mL) upregulated AT1R but not AT2R, mRNA, or protein. Ox-LDL degraded IkappaBalpha in cytoplasm and activated transcription factor NF-kappaB (P65) in HCAEC nuclear extract. Treatment of cells with the antioxidant alpha-tocopherol (10 to 50 micromol/L) attenuated ox-LDL-mediated degradation of IkappaBalpha and activation of NF-kappaB (P65) and inhibited the upregulation of AT1R mRNA and protein. The role of NF-kappaB signal transduction was further examined by use of an NF-kappaB inhibitor, caffeic acid phenethyl ester (CAPE). Pretreatment of cells with CAPE inhibited ox-LDL-mediated degradation of IkappaBalpha and NF-kappaB activation and inhibited ox-LDL-induced upregulation of AT1R expression. Incubation of cells with both ox-LDL and Ang II increased cell injury, measured as cell viability and LDH release, compared with either ox-LDL or Ang II alone. alpha-Tocopherol as well as the specific AT1R blocker CV11974 (candesartan) attenuated the cell-injurious effects of ox-LDL.
These observations suggest an important role of ox-LDL-mediated AT1R upregulation in cell injury. In this process, NF-kappaB activation seems to play a critical role in signal transduction. These findings provide a basis for the use of antioxidants and AT1R blockers in designing therapy of atherosclerosis.
我们先前证明,血管紧张素II(Ang II)通过激活AT(1)受体,上调人冠状动脉内皮细胞(HCAECs)中氧化型低密度脂蛋白(ox-LDL)内皮受体LOX-1基因表达并促进ox-LDL的摄取。在本研究中,我们调查了ox-LDL对Ang II受体(AT1R和AT2R)的调节作用以及氧化还原敏感转录因子NF-κB在此过程中的作用。
将HCAECs与ox-LDL孵育24小时。ox-LDL(10至40微克蛋白/毫升)上调AT1R,但不上调AT2R的mRNA或蛋白。ox-LDL降解细胞质中的IkappaBalpha并激活HCAEC核提取物中的转录因子NF-κB(P65)。用抗氧化剂α-生育酚(10至50微摩尔/升)处理细胞可减弱ox-LDL介导的IkappaBalpha降解和NF-κB(P65)激活,并抑制AT1R mRNA和蛋白的上调。通过使用NF-κB抑制剂咖啡酸苯乙酯(CAPE)进一步研究NF-κB信号转导的作用。用CAPE预处理细胞可抑制ox-LDL介导的IkappaBalpha降解和NF-κB激活,并抑制ox-LDL诱导的AT1R表达上调。与单独使用ox-LDL或Ang II相比,将细胞与ox-LDL和Ang II一起孵育会增加细胞损伤,以细胞活力和乳酸脱氢酶释放来衡量。α-生育酚以及特异性AT1R阻滞剂CV11974(坎地沙坦)减弱了ox-LDL的细胞损伤作用。
这些观察结果表明ox-LDL介导的AT1R上调在细胞损伤中起重要作用。在此过程中,NF-κB激活似乎在信号转导中起关键作用。这些发现为在设计动脉粥样硬化治疗方案中使用抗氧化剂和AT1R阻滞剂提供了依据。